Trial of Psilocybin versus Escitalopram for Depression
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients received psychological support. The primary outcome was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16; scores range from 0 to 27, with higher scores indicating greater depression) at week 6. There were 16 secondary outcomes, including QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ≤5) at week 6. RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. The mean (±SE) changes in the scores from baseline to week 6 were -8.0±1.0 points in the psilocybin group and -6.0±1.0 in the escitalopram group, for a between-group difference of 2.0 points (95% confidence interval [CI], -5.0 to 0.9) (P = 0.17). A QIDS-SR-16 response occurred in 70% of the patients in the psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22 percentage points (95% CI, -3 to 48); QIDS-SR-16 remission occurred in 57% and 28%, respectively, for a between-group difference of 28 percentage points (95% CI, 2 to 54). Other secondary outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for multiple comparisons. The incidence of adverse events was similar in the trial groups. CONCLUSIONS: On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants. (Funded by the Alexander Mosley Charitable Trust and Imperial College London's Centre for Psychedelic Research; ClinicalTrials.gov number, NCT03429075.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two recent psilocybin clinical trials, ~95% of all volunteers were eliminated on the basis of exclusion criteria”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [8]
In the citing paper
“Amelioration of symptomatic depression in pilot studies of major depressive disorder, including those that compared psilocybin with escitalopram 8,9 and that investigated its use in treatment-resistant depression, 10 has suggested therapeutic potential for this agent.”
From Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022) · cites this paper as [9]
In the citing paper
“Studies have used inactive placebos (e.g., [17, 35]), active placebos whose effects considerably differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39])”
In the citing paper
“Contemporary clinical studies have involved one to three dosing sessions (e.g., [38, 39, 117])”
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [26]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Cited by
Items 301–400 of 1,001
Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation
Modlin, N. L., Miller, T. M., Rucker, J., Kirlić, N., Lennard-Jones, M., Schlosser, D. A., & Aaronson, S. T. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.077 · Cited by 32
A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortex
Luppi, A. I., Girn, M., Rosas, F. E., Timmermann, C., Roseman, L., Erritzøe, D., Nutt, D. J., Stamatakis, E. A., Spreng, R. N., Xing, L., et al. (2023) · Brain · doi:10.1093/brain/awad311 · Cited by 35
“19 Evidence is presently strongest for depression 20-24 but suggestive results have also been found for end-of-life distress in terminal patients, 25,26 tobacco addiction 27 and alcoholism.”
Self-citationPogorelov, V. M., Rodriguiz, R. M., Roth, B. L., & Wetsel, W. C. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1233743 · Cited by 36
Falchi-Carvalho, M., Wießner, I., Silva, S. R. B., Maia, L. O., Barros, H., Laborde, S., Arichelle, F., Tullman, S., Silva-Costa, N., Assunção, A., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.12.006 · Cited by 37
Prescription Psychedelics: The Road from FDA Approval to Clinical Practice
Lamkin, M. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.07.033 · Cited by 31
On Minimizing Risk and Harm in the Use of Psychedelics
Evans, J., Aixalà, M., Anderson, B. T., Brennan, W., Bremler, R., Breeksema, J. J., Burback, L., Calder, A. E., Carhart-Harris, R. L., Cheung, K., et al. (2025) · Psychiatric Research and Clinical Practice · doi:10.1176/appi.prcp.20240128 · Cited by 34
Self-citationHuman brain changes after first psilocybin use
Lyons, T., Spriggs, M. J., Kerkelä, L., Rosas, F. E., Roseman, L., Mediano, P. A. M., Timmermann, C., Oestreich, L., Pagni, B. A., Zeifman, R. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71962-3 · Cited by 41
Self-citationWiens, K. R., Brooks, N. A. H., Riar, I., Greuel, B. K., Lindhout, I. A., & Klegeris, A. (2024) · Molecules · doi:10.3390/molecules29215084 · Cited by 30
“Likely due to this stimulatory activity of its main metabolite, psilocybin has emerged as a promising novel antidepressant, as shown in multiple human clinical trials, significantly alleviating symptoms in various forms of depression, including in treatment-resistant cases [30–32].”
BackgroundVirtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy
Sekula, A. D., Downey, L. A., & Puspanathan, P. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.813746 · Cited by 36
“…have been reported to be one of the most or the single most influential experience of one’s life (Griffiths et al., 2006), and have been proposed to have the potential to lead to pivotal changes in one’s feelings, attitudes, behaviors and even personality traits (Brouwer and Carhart-Harris, 2021).”
BackgroundAnimal Behavior in Psychedelic Research
Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000590 · Cited by 32
Jones, G. M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127304 · Cited by 33
“In modern Western science, a number of trials have demonstrated that psilocybin can act as an effective treatment for severe depression when used in therapeutic contexts (Carhart-Harris et al., 2016, 2021; Davis et al., 2020; Goldberg et al., 2020; Griffiths et al., 2016).”
BackgroundMusic programming for psilocybin-assisted therapy: Guided Imagery and Music-informed perspectives
Messell, C., Summer, L., Bonde, L. O., Beck, B. D., & Stenbæk, D. S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.873455 · Cited by 34
Boehnke, K. F., Cox, K., Weston, C. L., Herberholz, M., Glynos, N. G., Kolbman, N., Fields, C. W., Barron, J., & Kruger, D. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1224551 · Cited by 32
New Paradigms of Old Psychedelics in Schizophrenia
Mahmood, D., Alenezi, S. K., Anwar, M. J., Azam, F., Qureshi, K. A., & Jaremko, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050640 · Cited by 29
“finding from a recent phase 2, double-blind, randomized, controlled clinical study involving patients with moderate-to-severe major depressive disorder reported that psilocybin exhibited superior efficacy over escitalopram [67].”
BackgroundWojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Maćkowiak, M., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010100 · Cited by 30
“Among serotonergic hallucinogens, psilocybin is currently the most studied compound, as it has proven to be at least as effective as common antidepressant drugs [20].”
BackgroundPsychedelics and sexual functioning: a mixed-methods study
Barba, T., Kettner, H., Radu, C., Peill, J. M., Roseman, L., Nutt, D. J., Erritzøe, D., Carhart-Harris, R. L., & Giribaldi, B. (2024) · Scientific Reports · doi:10.1038/s41598-023-49817-4 · Cited by 30
“Moreover, the psychedelic intervention performed significantly better than the SSRI on secondary outcomes measuring well-being, general functioning and anhedonia 7 .”
BackgroundInfluentialSelf-citationGuo, Q., Guo, L., Yong, W., & Shang, S. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116018 · Cited by 30
Klaiber, A., Schmid, Y., Becker, A., Straumann, I., Erne, L., Jelušić, A., Thomann, J., Luethi, D., & Liechti, M. E. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03116-2 · Cited by 32
Wang, E. Y., Mathai, D. S., Gukasyan, N., Nayak, S. M., & Garcia‐Romeu, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-78736-1 · Cited by 37
The safety of psilocybin-assisted psychotherapy: A systematic review
de Freitas, R. R., Gotsis, E. S., Gallo, A. T., Fitzgibbon, B. M., Bailey, N. W., & Fitzgerald, P. B. (2024) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674241289024 · Cited by 29
Rucker, J., Jafari, H., Mantingh, T., Bird, C., Modlin, N. L., Knight, G., Reinholdt, F., Day, C., Carter, B., & Young, A. H. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-056091 · Cited by 29
5-HT2A SNPs Alter the Pharmacological Signaling of Potentially Therapeutic Psychedelics
Schmitz, G. P., Jain, M. K., Slocum, S. T., & Roth, B. L. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00815 · Cited by 31
Dougherty, R. F., Clarke, P., Atli, M., Kuc, J., Schlosser, D. A., Dunlop, B. W., Hellerstein, D. J., Aaronson, S. T., Zisook, S., Young, A. H., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06432-5 · Cited by 35
Self-citationKelly, T. J., Bonniwell, E. M., Mu, L., Liu, X., Hu, Y., Friedman, V., Yu, H., Su, W., McCorvy, J. D., & Liu, Q.-S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01744-8 · Cited by 35
“A single dose of psilocybin confers a reduction in depression and anxiety symptoms for weeks to months [13, 14] with comparable ef fi cacy to the selective-serotonin reuptake inhibitor escitalopram [11].”
LSD-induced changes in the functional connectivity of distinct thalamic nuclei
Pizzi, S. D., Chiacchiaretta, P., Sestieri, C., Ferretti, A., Tullo, M. G., Penna, S. D., Martinotti, G., ONOFRJ, M. C., Roseman, L., Timmermann, C., et al. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120414 · Cited by 35
Self-citationSafety pharmacology of acute psilocybin administration in healthy participants
Straumann, I., Holze, F., Becker, A., Ley, L., Halter, N., & Liechti, M. E. (2024) · Neuroscience Applied · doi:10.1016/j.nsa.2024.104060 · Cited by 32
Buot, A., Pallares, C., Oganesyan, A., Dauré, C., Bonnelle, V., Burguière, E., Dos Santos, J. F. A., N’Diaye, K., Ljuslin, M., Smith, P., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-39812-0 · Cited by 28
“This observation further suggests that moderate to high doses are necessary to obtain a therapeutic effect, which is coherent with preliminary data in OCD 17 , as well as in other pathologies 39–41 .”
ResultThe Mystical Experience Questionnaire 4-Item and Challenging Experience Questionnaire 7-Item
Strickland, J. C., Garcia‐Romeu, A., & Johnson, M. W. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0046 · Cited by 30
Hsu, T., Tsai, C., Kao, Y., Thompson, T., Carvalho, A. F., Yang, F., Tseng, P., Hsu, C.-W., Yu, C., Tu, Y., et al. (2024) · BMJ · doi:10.1136/bmj-2023-078607 · Cited by 38
A multi-institutional investigation of psilocybin’s effects on mouse behavior
Lu, O., White, K., Raymond, K. B., Liu, C. J., Klein, A. S., Green, N., Vaillancourt, S., Gallagher, A. J., Shindy, L., Li, A., et al. (2026) · Nature Neuroscience · doi:10.1101/2025.04.08.647810 · Cited by 34
“For example, psilocybin, which has arguably received the greatest attention because of its promise for treating depression, failed to produce stronger antidepressant effects than the selective serotonin reuptake inhibitor escitalopram 20 .”
Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations
Ortiz, C. E., Dourron, H. M., Sweat, N. W., Garcia‐Romeu, A., MacCarthy, S., Anderson, B. T., & Hendricks, P. S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109127 · Cited by 29
Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder
Ledwos, N., Rodas, J. D., Husain, M. I., Feusner, J. D., & Castle, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140009 · Cited by 30
“In particular, a resurgence in research involving patients with end-of-life anxiety and depression has demonstrated supportive evidence that psilocybin combined with psychotherapy is both safe and efficacious in reducing psychological symptoms (Agin-Liebes et al., 2020; Carhart-Harris et al., 2021; Davis et al., 2021;…”
BackgroundSoliman, P., Curley, D. E., Capone, C., Eaton, E. M., & Haass‐Koffler, C. L. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06598-6 · Cited by 31
Psychedelic therapy in depression and substance use disorders
Korkmaz, N. D., Çıkrıkçılı, U., Akan, M., & Yücesan, E. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16421 · Cited by 32
“This result shows that psilocybin can be at least as effective as an antidepressant (Carhart-Harris et al., 2021).”
Mindlin, I., Herzog, R. A., Belloli, L. M. L., Manasova, D., Monge-Asensio, M., Vohryzek, J., Escrichs, A., Alnagger, N., Nùñez, P., Gosseries, O., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06852-9 · Cited by 33
“Atthesametime,overthepastyearsthe use of psychedelics for treating mental health disorders has shown promising results in conditions such as depression 21 – 24 and obsessive-compulsive disorder 25 .”
Psilocybin for major depressive disorder: a systematic review of randomized controlled studies
Li, L., Mo, Y., Shi, Z.-M., Huang, X., Ning, Y.-P., Wu, H., Yang, X.-H., & Zheng, W. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1416420 · Cited by 30
“Novel pharmacological interventions, such as ketamine/ esketamine (7) or psilocybin (8), have shown positive results in treating patients with MDD and have the potential to provide better protection.”
BackgroundResultInfluentialPsilocybin increases emotional empathy in patients with major depression
Jungwirth, J., von Rotz, R., Dziobek, I., Vollenweider, F. X., & Preller, K. H. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02875-0 · Cited by 31
“It showed promising results in the treatment of depression [24 – 28], end-of-life anxiety [29, 30] and alcoholism [31].”
Pellegrini, L., Fineberg, N. A., O'Connor, S., de Souza, A. M. F. L. P., Godfrey, K., Reed, S., Peill, J. M., Healy, M. P., Rohani-Shukla, C., Lee, H., et al. (2025) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2025.152619 · Cited by 32
“Furthermore, we did not find improvement in depressive symptoms in OCD, which contrasts with previous findings in patients with depression [14], though with a 25 mg dose.”
Self-citationPsilocybin triggers an activity-dependent rewiring of large-scale cortical networks
Jiang, Q., Shao, L.-X., Yao, S., Savalia, N. K., Gilbert, A. D., Davoudian, P. A., Nothnagel, J. D., Tian, G., Hung, J. T. S., Lai, H. M., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.009 · Cited by 36
Vasiliu, O. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.884143 · Cited by 34
“In conclusion, this trial did not support the efficacy of psilocybin in comparison with escitalopram, at least in the main outcome treatment (Carhart-Harris et al., 2021).”
BackgroundMethodResultInfluentialBurmester, D., Madsen, M. K., Szabó, A., Aripaka, S. S., Stenbæk, D. S., Frøkjær, V. G., Elfving, B., Mikkelsen, J. D., Knudsen, G. M., & Fisher, P. M. (2022) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2022.100163 · Cited by 28
Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing
Cairns, E. A., Benson, M. J., Bedoya‐Pérez, M. A., Macphail, S. L., Mohan, A., Cohen, R., Sachdev, P. S., & McGregor, I. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1142680 · Cited by 29
“Examples include the use of ketamine and psilocybin for depression (Thomas et al., 2017; Rosenblat et al., 2019; Carhart-Harris et al., 2021; Goodwin et al., 2022) and MDMA for PTSD (Mitchell et al.”
BackgroundSimonsson, O., Carlbring, P., Carhart-Harris, R. L., Davis, A. K., Nutt, D. J., Griffiths, R. R., Erritzøe, D., & Goldberg, S. B. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115349 · Cited by 27
Self-citationKaminski, D., & Reinert, J. P. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231205645 · Cited by 31
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Barksdale, B. R., Doss, M. K., Fonzo, G. A., & Nemeroff, C. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00322 · Cited by 28
Villiger, D. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2357669 · Cited by 31
“1 The present results are promising and suggest efficacy in the treatment of major depressive disorder (Carhart-Harris, Bolstridge, et al., 2016; Carhart-Harris et al., 2018, 2021; Goodwin et al., 2022; Palhano-Fontes et al., 2019; Raison et al., 2023; Reiff et al., 2020; Rotz et al., 2023; Sanches…”
Psilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 28
Wall, M. B., Demetriou, L., Giribaldi, B., Roseman, L., Ertl, N., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230751 · Cited by 27
Self-citationMulti-metric evaluations of acute psychedelic effects on fMRI brain entropy
McCulloch, D. E.-W., Olsen, A. S., Ozenne, B., Larsen, K. O., Stenbæk, D. S., Armand, S., Madsen, M. K., Knudsen, G. M., & Fisher, P. M. (2026) · Nature Communications · doi:10.1038/s41467-026-74215-5 · Cited by 31
Humphreys, K. N., Korthuis, P. T., Stjepanović, D., & Hall, W. (2024) · Annual Review of Psychology · doi:10.1146/annurev-psych-020124-023532 · Cited by 32
Adverse psychiatric effects of psychedelic drugs: a systematic review of case reports
Yildirim, B., Sahin, S. S., Gee, A., Jauhar, S., Rucker, J., Salgado‐Pineda, P., Pomarol‐Clotet, E., & McKenna, P. J. (2024) · Psychological Medicine · doi:10.1017/s0033291724002496 · Cited by 32
“Four recent trials (Carhart-Harris et al., 2021; Goodwin et al., 2022; Raison et al., 2023; von Rotz et al., 2023) (one of them large, N = 233; Goodwin et al., 2022) have found evidence for psilocybin ’ s effectiveness in major depressive disorder, leading to the FDA designating it a ‘ breakthrough…”
Psychedelics for the Treatment of Obsessive–Compulsive Disorder: Efficacy and Proposed Mechanisms
Collins, H. M. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae057 · Cited by 29
Effects of classic psychedelic drugs on turbulent signatures in brain dynamics
Cruzat, J., Perl, Y. S., Escrichs, A., Vohryzek, J., Timmermann, C., Roseman, L., Luppi, A. I., Ibáñez, A. M., Nutt, D. J., Carhart-Harris, R. L., et al. (2022) · Network Neuroscience · doi:10.1162/netn_a_00250 · Cited by 31
Self-citationRossi, G. N., Hallak, J. E. C., Bouso, J. C., & SANTOS, R. G. D. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2066650 · Cited by 29
Pharmacological Treatments for Anhedonia
Klein, M. E., Grice, A. B., Sheth, S., Go, M., & Murrough, J. W. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_357 · Cited by 29
Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.12.042 · Cited by 28
Weiss, B., Erritzøe, D., Giribaldi, B., Nutt, D. J., & Carhart-Harris, R. L. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231167848 · Cited by 28
“To assess the validity of the QIDS-SR16 using data from Carhart-Harris et al. (2021), QIDS-SR16 items were compared with similar items from other scales that would be predicted to show a similar pattern of differential treatment response.”
BackgroundMethodResultInfluentialSelf-citationThe psychedelic effects of cannabis: A review of the literature
Wolinsky, D., Barrett, F. S., & Vandrey, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231209194 · Cited by 28
“…related to a terminal illness (Griffiths et al., 2016; Grob et al., 2011; Muttoni et al., 2019; Ross et al., 2016), major depressive disorder (Carhart-Harris et al., 2016a, 2021; Davis et al., 2021; D’Souza et al., 2022; Goodwin et al., 2023), tobacco use disorder (Johnson et al., 2014,…”
BackgroundPsilocybin-induced default mode network hypoconnectivity is blunted in alcohol-dependent rats
Reinwald, J., Schmitz, C. N., Skorodumov, I., Kuchař, M., Weber‐Fahr, W., Spanagel, R., & Meinhardt, M. W. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02690-1 · Cited by 28
“It is important to note that most studies in AUD typically use higher dosages of psilocybin ([11]; second treatment step) compared to other psychiatric diseases, such as major depression [1].”
Pharmacological and behavioural effects of tryptamines present in psilocybin‐containing mushrooms
Rakoczy, R. J., Runge, G. N., Sen, A. K., Sandoval, O., Wells, H. G., Nguyen, Q., Roberts, B., Sciortino, J. H., Gibbons, W. J., Friedberg, L. M., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.16466 · Cited by 28
(2024) · doi:10.1177/02698811231215420 · Cited by 25
“Fourteen of the identified studies used psilocybin (Anderson et al., 2020; Bogenschutz et al., 2015, 2022; Carhart-Harris et al., 2016, 2021; Davis et al., 2021; Goodwin et al., 2022; Griffiths et al., 2016; Grob et al., 2011; Johnson et al., 2014; Moreno et al., 2006; Ross et al., 2016; Schneier…”
BackgroundPsychological effects of psychedelics in adolescents
Izmi, N., Carhart-Harris, R. L., & Kettner, H. (2024) · Frontiers in Child and Adolescent Psychiatry · doi:10.3389/frcha.2024.1364617 · Cited by 31
Self-citationCo-design of Guidance for Patient and Public Involvement in Psychedelic Research
Close, J. B., Bornemann, J., Piggin, M., Jayacodi, S., Luan, L. X., Carhart-Harris, R. L., & Spriggs, M. J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727496 · Cited by 27
Self-citationDijkstra, J. M., & Nagatsu, T. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-021-02450-9 · Cited by 28
Psychedelics and schizophrenia: Distinct alterations to Bayesian inference
Rajpal, H., Mediano, P. A. M., Rosas, F. E., Timmermann, C., Brugger, S. P., Muthukumaraswamy, S. D., Seth, A. K., Bor, D., Carhart-Harris, R. L., & Jensen, H. J. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119624 · Cited by 29
Self-citationThe use of classic psychedelics among adults: a Danish online survey study
Juul, T. S., Jensen, M. E., & Fink‐Jensen, A. (2022) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2022.2125069 · Cited by 30
“In recent clinical studies on classic psychedelics, the most commonly reported acute adverse events have been headache, nausea, anxiety, dysphoria, tachycardia, and elevated blood pressure, while there have been no cases of serious adverse events [23,24,38].”
BackgroundJensen, M. E., Stenbæk, D. S., Juul, T. S., Fisher, P. M., Ekstrøm, C. T., Knudsen, G. M., & Fink‐Jensen, A. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-066019 · Cited by 28
Isham, A., Elf, P., & Jackson, T. P. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1051478 · Cited by 27
“, 2018), more recent findings show no superiority of psychedelics over traditional antidepressants in terms of treatment efficacy (Carhart-Harris et al., 2021).”
BackgroundThe separation distress hypothesis of depression – an update and systematic review
Watt, D. F. (2023) · Neuropsychoanalysis · doi:10.1080/15294145.2023.2240340 · Cited by 26
Converging circuits between pain and depression: the ventral tegmental area as a therapeutic hub
Flores-García, M., Rizzo, A., Garçon-Poca, M. Z., Fernández‐Dueñas, V., & Bonaventura, J. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1278023 · Cited by 29
“More recently, psychedelic drugs, which may also act through the serotonergic system but targeting serotonin receptors instead of serotonin reuptake or degradation, have been proposed as novel treatments for depression (Carhart-Harris et al., 2016; Griffiths et al., 2016; Reiff et al., 2020; Carhart-Harris et al., 202…”
BackgroundPreclinical models of treatment-resistant depression: challenges and perspectives
Kolasa, M., & Faron‐Górecka, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00542-9 · Cited by 27
“Previous pilot studies focusing on major depressive disorder, which encompassed comparisons between psilocybin and escitalopram [66] along with an exploration of its utility in treatment-resistant depression [67], have provided insights into the therapeutic prospects of this compound.”
ResultMolecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 27
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 28
“Psilocybin has demonstrated rapid and sustained antidepressant and anxiolytic effects across several phase 2 randomized controlled trials 3,6,7 (with comparators being placebo, SSRI or lower doses of psilocybin), earning Breakthrough Therapy designation from the US Food and Drug Administration…”
Self-citationWilliams, Z. J., Barnett, H., & Szigeti, B. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.4809 · Cited by 29
Lee, S., Yu, J. S., Lee, S. R., & Kim, K. H. (2021) · Natural Product Reports · doi:10.1039/d1np00049g · Cited by 24
The illusion of knowledge in the emerging field of psychedelic research
Oña, G., Kohek, M., & Bouso, J. C. (2022) · New Ideas in Psychology · doi:10.1016/j.newideapsych.2022.100967 · Cited by 28
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 26
“…et al., 2016; Grob et al., 2011; Ross et al., 2016), obsessive-compulsive disorder (Moreno et al., 2006), treatment-resistant depression (Carhart-Harris et al., 2016a), major depressive disorder (Carhart-Harris et al., 2021; Davis et al., 2021), and tobacco dependence (Johnson et al., 2017).”
BackgroundInfluentialPsychedelic innovations and the crisis of psychopharmacology
Langlitz, N. (2022) · BioSocieties · doi:10.1057/s41292-022-00294-4 · Cited by 28
The Health and Clinical Benefits of Medicinal Fungi
Hobbs, C. (2023) · Advances in biochemical engineering, biotechnology · doi:10.1007/10_2023_230 · Cited by 30
Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample
Kvam, T.-M., Uthaug, M. V., Andersen, K. A. A., Refsum, B. B., Tunstad, P. A., Stewart, L. H., Jacobsen, H. B., & Grønnerød, C. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1287196 · Cited by 25
“This is in line with previous clinical research showing promising results in the treatment of depression, alcohol use disorder and other conditions (3, 5, 6).”
BackgroundResultGattuso, J. J., Wilson, C., Hannan, A. J., & Renoir, T. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.16017 · Cited by 28
Psychedelics and the ‘inner healer’: Myth or mechanism?
Peill, J. M., Marguilho, M., Erritzøe, D., Barba, T., Greenway, K. T., Rosas, F. E., Timmermann, C., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241239206 · Cited by 26
“The inclusion of the present inner healer item in a DB-RCT of psilocybin versus escitalopram for depression was a small exper-iment within a larger one (Carhart-Harris et al., 2021).”
BackgroundMethodInfluentialSelf-citationAboharb, F., Davoudian, P. A., Shao, L.-X., Liao, C., Rzepka, G. N., Wojtasiewicz, C., Indajang, J., Dibbs, M., Rondeau, J. A., Sherwood, A. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56850-6 · Cited by 27
“We find different types of dose dependence for psilocybin’s effects on c-Fos expression that is region-specific.”
Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review
Watford, T., & Masood, N. (2024) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1120 · Cited by 23
Singh, N., Hazari, P. P., Mittal, P., Yadav, S. K., Kumar, N., Mishra, G., Dahiya, S., & Mishra, A. K. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177737 · Cited by 24
Erkizia-Santamaría, I., Horrillo, I., Martínez-Álvarez, N., Pérez-Martínez, D., Rivero, G., Erdozain, A. M., Meana, J. J., & Ortega, J. E. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03421-4 · Cited by 26
Højlund, M., Kafalı, H. Y., Kırmızı, B., Fusar‐Poli, P., Correll, C. U., Cortese, S., Sabé, M., Fiedorowicz, J. G., Saraf, G., Zein, J., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.09.011 · Cited by 25
Self-citationExperiences of psilocybin treatment for clinical conditions: A qualitative meta‐synthesis
Crowe, M., Manuel, J., Carlyle, D., & Lacey, C. J. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13127 · Cited by 25
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders
Rhee, T. G., Davoudian, P. A., Sanacora, G., & Wilkinson, S. T. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103818 · Cited by 24
Raithatha, S. A., Hagel, J. M., Matinkhoo, K., Yu, L. X., Press, D., Cook, S. G., Sharma, G., Dhananjaya, D., Jensen, G., Lee, J. B., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01225 · Cited by 24
Namiot, E. D., Smirnovová, D., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03031-6 · Cited by 27
Pharmacological and non-pharmacological predictors of the LSD experience in healthy participants
Vizeli, P., Studerus, E., Holze, F., Schmid, Y., Dolder, P. C., Ley, L., Straumann, I., Becker, A., Müller, F., Arikci, D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03074-9 · Cited by 27
“Indeed, this has been also the conclusion of a recent review [64] and has already been done in several phase II trials with psychedelics [3, 7] and phase III trials with MDMA [65, 66].”
ResultHlynsson, J. I., Skúlason, S., Andersson, G., & Carlbring, P. (2025) · Psychiatric Quarterly · doi:10.1007/s11126-025-10208-9 · Cited by 27
Not in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Meling, D., & Scheidegger, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1100058 · Cited by 24
Perceptions of psychedelic-assisted therapy among Black Americans
Carter, S. E., Packard, G. A., Coghlan, C., George, J. R., Brown, A. J., Ching, T. H. W., Julian, J., & Maples‐Keller, J. L. (2023) · Journal of Mood and Anxiety Disorders · doi:10.1016/j.xjmad.2023.100023 · Cited by 24
“Psilocybin assisted therapy is associated with reductions in depressive and anxiety symptoms and increases in mental wellbeing and flourishing in those with depression [8].”
Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., Roméo, B., & Benyamina, A. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad078 · Cited by 23
Dworkin, R. H., Anderson, B. T., Andrews, N., Edwards, R. R., Grob, C. S., Ross, S., Satterthwaite, T. D., & Strain, E. C. (2022) · Journal of Pain · doi:10.1016/j.jpain.2022.05.003 · Cited by 27
Skepticism about Recent Evidence That Psilocybin “Liberates” Depressed Minds
Doss, M. K., Barrett, F. S., & Corlett, P. R. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00461 · Cited by 22
Menon, V., Ramamurthy, P., Venu, S., & Andrade, C. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13778 · Cited by 28
“At day 7, the pooled RR for PAT versus control interventions was 3.42 (95% CI, 2.35–4.97, I 2 = 0%; 4 RCTs [25–28]; n = 373) (Figure 4A) for study-defined response rate and 3.66 (95% CI, 2.26–5.92, I2 = 0%; 4 RCTs [25–28]; n = 373) (Figure 4B) for study-defined remission rate.”
InfluentialGong, P., Wang, J., Long, H., Yang, W., Chen, X., Li, N., Chen, F., Zhang, J., & Guo, Y. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70080 · Cited by 24
Metadata
- Authors
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- From the Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-15
- Volume
- 384
- Issue
- 15
- Pages
- 1402-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3156937150
- Cited by
- 1,391
- References
- 26
- Citations by year
- 2026: 200 · 2025: 278 · 2024: 287 · 2023: 284 · 2022: 247 · 2021: 92
- FWCI
- 154.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alex Mosley Charitable Trust (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, escitalopram, major depressive disorder, antidepressant efficacy, psychedelic therapy, selective serotonin reuptake inhibitors, depression remission, treatment-resistant depression, psychological support, hallucinations, dissociation, synesthesia, anxiety disorders
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Citalopram, Antidepressive Agents, Second-Generation, Young Adult, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.